Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1?,25-dihydroxyvitamin D2 (1?,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease. Doxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aluminum hydroxide | The serum concentration of Aluminum hydroxide can be increased when it is combined with Doxercalciferol. |
| Danazol | Danazol may increase the hypercalcemic activities of Doxercalciferol. |
| Sucralfate | The serum concentration of Sucralfate can be increased when it is combined with Doxercalciferol. |
| Orlistat | Orlistat can cause a decrease in the absorption of Doxercalciferol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium sulfate | The serum concentration of Magnesium sulfate can be increased when it is combined with Doxercalciferol. |
| Magnesium oxide | The serum concentration of Magnesium oxide can be increased when it is combined with Doxercalciferol. |
| Magnesium salicylate | The serum concentration of Magnesium salicylate can be increased when it is combined with Doxercalciferol. |
| Magaldrate | The serum concentration of Magaldrate can be increased when it is combined with Doxercalciferol. |
| Magnesium hydroxide | The serum concentration of Magnesium hydroxide can be increased when it is combined with Doxercalciferol. |
| Magnesium trisilicate | The serum concentration of Magnesium trisilicate can be increased when it is combined with Doxercalciferol. |
| Magnesium chloride | The serum concentration of Magnesium chloride can be increased when it is combined with Doxercalciferol. |
| Magnesium carbonate | The serum concentration of Magnesium carbonate can be increased when it is combined with Doxercalciferol. |
| Talc | The serum concentration of Talc can be increased when it is combined with Doxercalciferol. |
| Magnesium citrate | The serum concentration of Magnesium citrate can be increased when it is combined with Doxercalciferol. |
| Magnesium silicate | The serum concentration of Magnesium silicate can be increased when it is combined with Doxercalciferol. |
| Hydrotalcite | The serum concentration of Hydrotalcite can be increased when it is combined with Doxercalciferol. |
| Magnesium aspartate | The serum concentration of Magnesium aspartate can be increased when it is combined with Doxercalciferol. |
| Magnesium peroxide | The serum concentration of Magnesium peroxide can be increased when it is combined with Doxercalciferol. |
| Magnesium gluconate | The serum concentration of Magnesium gluconate can be increased when it is combined with Doxercalciferol. |
| Magnesium orotate | The serum concentration of Magnesium orotate can be increased when it is combined with Doxercalciferol. |
| Magnesium levulinate | The serum concentration of Magnesium levulinate can be increased when it is combined with Doxercalciferol. |
| Magnesium lactate | The serum concentration of Magnesium lactate can be increased when it is combined with Doxercalciferol. |
| Digoxin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Digoxin. |
| Acetyldigitoxin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Acetyldigitoxin. |
| Deslanoside | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Deslanoside. |
| Ouabain | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Ouabain. |
| Digitoxin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Digitoxin. |
| Oleandrin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Oleandrin. |
| Cymarin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Cymarin. |
| Proscillaridin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Proscillaridin. |
| Metildigoxin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Metildigoxin. |
| Lanatoside C | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Lanatoside C. |
| Gitoformate | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Gitoformate. |
| Acetyldigoxin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Acetyldigoxin. |
| Peruvoside | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Peruvoside. |
| Mineral oil | Mineral oil can cause a decrease in the absorption of Doxercalciferol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methyclothiazide | The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Doxercalciferol. |
| Bendroflumethiazide | The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Doxercalciferol. |
| Benzthiazide | The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Doxercalciferol. |
| Cyclothiazide | The risk or severity of hypercalcemia can be increased when Cyclothiazide is combined with Doxercalciferol. |
| Hydroflumethiazide | The risk or severity of hypercalcemia can be increased when Hydroflumethiazide is combined with Doxercalciferol. |
| Chlorothiazide | The risk or severity of hypercalcemia can be increased when Chlorothiazide is combined with Doxercalciferol. |
| Hydrochlorothiazide | The risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Doxercalciferol. |
| Trichlormethiazide | The risk or severity of hypercalcemia can be increased when Trichlormethiazide is combined with Doxercalciferol. |
| Polythiazide | The risk or severity of hypercalcemia can be increased when Polythiazide is combined with Doxercalciferol. |
| Mebutizide | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Doxercalciferol. |
| Cyclopenthiazide | The risk or severity of hypercalcemia can be increased when Cyclopenthiazide is combined with Doxercalciferol. |
| Buthiazide | The risk or severity of hypercalcemia can be increased when Buthiazide is combined with Doxercalciferol. |
| Calcitriol | The risk or severity of adverse effects can be increased when Calcitriol is combined with Doxercalciferol. |
| Calcifediol | The risk or severity of adverse effects can be increased when Calcifediol is combined with Doxercalciferol. |
| Ergocalciferol | The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Doxercalciferol. |
| Cholecalciferol | The risk or severity of adverse effects can be increased when Cholecalciferol is combined with Doxercalciferol. |
| Paricalcitol | The risk or severity of adverse effects can be increased when Paricalcitol is combined with Doxercalciferol. |
| Dihydrotachysterol | The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Doxercalciferol. |
| Alfacalcidol | The risk or severity of adverse effects can be increased when Alfacalcidol is combined with Doxercalciferol. |
| Seocalcitol | The risk or severity of adverse effects can be increased when Seocalcitol is combined with Doxercalciferol. |
| Inecalcitol | The risk or severity of adverse effects can be increased when Inecalcitol is combined with Doxercalciferol. |
| Becocalcidiol | The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Doxercalciferol. |
| Eldecalcitol | The risk or severity of adverse effects can be increased when Eldecalcitol is combined with Doxercalciferol. |
| 1alpha,24S-Dihydroxyvitamin D2 | The risk or severity of adverse effects can be increased when 1alpha,24S-Dihydroxyvitamin D2 is combined with Doxercalciferol. |
| Elocalcitol | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Doxercalciferol. |
| Maxacalcitol | The risk or severity of adverse effects can be increased when Maxacalcitol is combined with Doxercalciferol. |
| Vitamin D | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Vitamin D. |
| 1alpha-Hydroxyvitamin D5 | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with 1alpha-Hydroxyvitamin D5. |
| Previtamin D(3) | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Previtamin D(3). |
| Calcium acetate | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium acetate. |
| Calcium glucoheptonate | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium glucoheptonate. |
| Calcium chloride | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium chloride. |
| Calcium | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium. |
| Calcium carbonate | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium carbonate. |
| Calcium citrate | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium citrate. |
| Calcium gluconate | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium gluconate. |
| Calcium Phosphate | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium Phosphate. |
| Calcium glubionate anhydrous | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium glubionate anhydrous. |
| Calcium lactate | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium lactate. |
| Calcium lactate gluconate | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium lactate gluconate. |
| Calcium pangamate | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium pangamate. |
| Calcium levulinate | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium levulinate. |
| Calcium cation | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium cation. |
| Calcium polycarbophil | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium polycarbophil. |
| Colestipol | The serum concentration of Doxercalciferol can be decreased when it is combined with Colestipol. |
| Sevelamer | The serum concentration of Doxercalciferol can be decreased when it is combined with Sevelamer. |
| Colesevelam | The serum concentration of Doxercalciferol can be decreased when it is combined with Colesevelam. |
| Cholestyramine | The serum concentration of Doxercalciferol can be decreased when it is combined with Cholestyramine. |
| Flunisolide | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Flunisolide. |
| Beclomethasone dipropionate | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Beclomethasone dipropionate. |
| Betamethasone | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Betamethasone. |
| Fluticasone propionate | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Fluticasone propionate. |
| Fluocinolone acetonide | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Fluocinolone acetonide. |
| Triamcinolone | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Triamcinolone. |
| Prednisone | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Prednisone. |
| Fludrocortisone | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Fludrocortisone. |
| Hydrocortisone | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Hydrocortisone. |
| Prednisolone | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Prednisolone. |
| Methylprednisolone | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Methylprednisolone. |
| Trilostane | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Trilostane. |
| Budesonide | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Budesonide. |
| Dexamethasone | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Dexamethasone. |
| Corticotropin | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Corticotropin. |
| Cortisone acetate | The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Cortisone acetate. |